Publish with Us Search
Publish with Us
Cell Therapy & Engineering Connect

Cell Therapy & Engineering Connect

ISSN: 3105-3866

Ken-ichiro Kamei
Editor-in-Chief

Ken-ichiro Kamei

Ken-ichiro Kamei
Editor-in-Chief

View Profile

Cell Therapy & Engineering Connect is a dynamic, peer-reviewed, open-access journal dedicated to advancing the frontiers of cell engineering. The journal provides a platform for cutting-edge research across a wide range of topics, including genetic engineering, stem cell technologies, cell-based therapies, tissue engineering, immunoengineering, and neuroengineering.

Volumes 2
Articles 9
Volume: 2, 2026
Submit Article Join Our Editorial Board Become a Reviewer
Download Flyer
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Open Access Policy:
All articles published in the journal Cell Therapy & Engineering Connect are Gold Open Access, immediately available without any embargo period, and licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license. This license facilitates the unrestricted dissemination of articles, encouraging widespread sharing and utilization of valuable research contributions.

Publication Frequency:
Cell Therapy & Engineering Connect follows a continuous publication model and is licensed under Creative Commons Attribution 4.0 (CC BY 4.0).

Publication Charges:
There will be no article processing charges (APCs) for submissions made by December 31, 2026, and all articles will be published as Open Access. Furthermore, the journal does not levy any additional fees on authors, including editorial processing charges, language editing fees, colour charges, submission fees, membership fees, or any other supplementary charges.

Subject Categories:
Molecular Biology, Tissue Engineering and Regenerative Medicine, Synthetic Biology.

Article Template:
You are encouraged to use the template to format your article according to our guidelines. However, this is not mandatory, as our layout team will ensure all necessary adjustments are made after acceptance and prior to final publication.

Download Template

Target Audience:
Cell Therapy & Engineering Connect is tailored for researchers, clinicians, scientists, and engineers dedicated to advancing the field of cell engineering through innovative research in genetic engineering, stem cell technologies, cell-based therapies, tissue engineering, immunoengineering, and neuroengineering for applications in healthcare and biotechnology.

Ethics Statement:

All articles published by Cell Therapy & Engineering Connect adhere strictly to the ethical guidelines suggested by the Committee on Publication Ethics (COPE).  We execute a stringent peer-review procedure that meticulously assesses the originality, quality, and precision of the research we disseminate. We employ advanced tools to scrutinize the legitimacy of submitted content and maintain a firm zero-tolerance stance toward instances of plagiarism, data manipulation, or inappropriate authorship.

For further details, please review our comprehensive Publication Ethics and Integrity Guidelines.

Insights

More Insights

35 Days

Time to First Peer Review Decision

61 Days

Time to Final Acceptance

2 Days

Acceptance to First Online

Recent Updates

All Updates
Scifiniti Publishing and Sci-Train Successfully Hosted Webinar on "Building Living Tissues: New Horizons in Cell Therapy and Bioengineering"
Scifiniti Publishing and Sci-Train Successfully Hosted Webinar on "Building Living Tissues: New Horizons in Cell Therapy and Bioengineering"
2025-09-17
Announcing the Launch of Cell Engineering Connect
Announcing the Launch of Cell Engineering Connect
2024-10-01

Recent Articles

All Articles
Review Article

Available Online: 13 Mar 2026

AI-Enabled Generative Design of Immune Cells and Receptors for Programmable Immunity

Volume 2

Recent advances in generative artificial intelligence have begun to redefine the practice of cell and immune engineering. By learning the statistical and structural grammar of biological systems, generative models can now design T-cell receptors, chimeric antigen receptors, and synthetic immune circuits that meet complex objectives of affinity, stability, and specificity. When integrated into automated design–build–test–learn pipelines, these models enable continuous..

https://doi.org/Registering DOI
Research Article

Available Online: 28 Dec 2025

Characterizing Immunodeficiencies Using Entropy Phase Transitions as Signatures of the Status of the Immune System

Volume 2

https://doi.org/Registering DOI
Research Article

Published: 27 Oct 2025

High-Purity Production of Endothelial Cells from Human Pluripotent Stem Cells

Volume 1

https://doi.org/10.69709/CTEC.2025.154455
Review Article

Published: 26 May 2025

A Review on the Cell-Penetrating Peptides

Volume 1

The therapeutic potential of biomacromolecules in treating various diseases is undeniable; however, their application is significantly limited by the inherent barrier function of the cell membrane. Cell-penetrating peptides (CPPs), a class of small peptides comprising fewer than 30 amino acids, have garnered considerable attention due to their exceptional ability to traverse cell membranes. These peptides ease the intracellular delivery of..

https://doi.org/10.69709/CellEngC.2025.145023
Share
Help